Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

The targeting of oncogenic ‘driver’ kinases with small molecule inhibitors has proven to be a highly effective therapeutic strategy in selected non-small cell lung cancer (NSCLC) patients. However, acquired resistance to targeted therapies invariably arises and is a major limitation to patient care....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Davies, Kurtis D., Mahale, Sakshi, Astling, David P., Aisner, Dara L., Le, Anh T., Hinz, Trista K., Vaishnavi, Aria, Bunn, Paul A., Heasley, Lynn E., Tan, Aik-Choon, Camidge, D. Ross, Varella-Garcia, Marileila, Doebele, Robert C.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3862576/
https://ncbi.nlm.nih.gov/pubmed/24349229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0082236
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars